SEBI exonerates Piramal Pharma of listing and disclosure violations

SEBI’s proceedings against PPL transpired in two rounds - in the first round, an Adjudicating Officer closed the investigation, however SEBI decided to review the same.
SEBI and Piramal Pharma
SEBI and Piramal Pharma
Published on
3 min read

The Securities and Exchange Board of India (SEBI) on November 8 cleared Piramal Pharma Limited (PPL) of allegations concerning violations of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations.

Loading content, please wait...
Bar and Bench - Indian Legal news
www.barandbench.com